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In women, breast cancer is the most common cancer diagnosis and second most common cause of
cancer death. More than half of breast cancer patients will develop metastases to the bone, liver,
lung, or brain. Breast cancer brain metastases (BCBM) confers a poor prognosis, as current
therapeutic options of surgery, radiation, and chemotherapy rarely significantly extend life and are
considered palliative. Within the realm of chemotherapy, the last decade has seen an explosion of
novel chemotherapeutics involving targeting agents and unique dosage forms. We provide a
historical overview of BCBM chemotherapy, review the mechanisms of new agents such as polyADP ribose polymerase inhibitors, cyclin-dependent kinase 4/6 inhibitors, phosphatidyl inositol 3kinaseinhibitors, estrogen pathway antagonists for hormone-receptor positive BCBM; tyrosine
kinase inhibitors, antibodies, and conjugates for HER2+ BCBM; repurposed cytotoxic
chemotherapy for triple negative BCBM; and the utilization of these new agents and formulations
in ongoing clinical trials. The mechanisms of novel dosage formulations such as nanoparticles,
liposomes, pegylation, the concepts of enhanced permeation and retention, and drugs utilizing
these concepts involved in clinical trials are also discussed. These new treatments provide a
promising outlook in the treatment of BCBM.
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1. EPIDEMIOLOGY
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Second only to heart disease, cancer accounted for 23% of recorded deaths in 2014. In
women, lung cancer is the leading cause of cancer death, followed by breast cancer, and then
colorectal cancer. It is estimated in 2018 there will be more than 260,000 new cases of breast
cancer and more than 40,000 deaths as a result of the disease [1]. Breast cancer is one of the
most common cancer diagnoses in women, with a 1-in-8 total lifetime risk for diagnosis [2].
Though breast cancer may be diagnosed at any age, a recently published report placed the
average age of diagnosis at 50 years old [3]. This report also found that in those cases in
which information on ethnicity was available, 68% were Caucasian, 17% were African
American, and 11% were Hispanic.

Author Manuscript

Although not as common in men, breast cancer incidence within this population is
increasing. The incidence in men is typically associated with factors such as a high body
mass index, Klinefelter syndrome, gynecomastia, liver disease, testicular disease,
alcoholism, and radiation exposure. Male breast cancer is most comparable to breast cancer
that presents in postmenopausal women, but with a few distinct differences. In men, breast
cancer is typically discovered at an older age and presents at a more advanced stage. In
addition, male breast cancer has higher rates of estrogen and progesterone receptor positivity
than female breast cancer. There is also evidence that genetic predisposition plays a larger
role in developing breast cancer in males [4].
One of the biggest challenges of treating breast cancer is its propensity to metastasize to
other areas of the body, including liver, bone, lung, and brain. After lung cancer, breast
cancer is the second most common source of brain metastases [5] (Figure 1). Of patients
diagnosed with breast cancer, between 10–15% will develop brain metastases [6] with the
median time of presentation 2-3 years after initial diagnosis [7]. In about 30% of breast
cancer patients, metastatic lesions in the brain were found post-mortem [8–11]. Brain
metastases of breast cancer are associated with limited survival and a lower quality of life.

Author Manuscript

Some risk factors that have been associated with the development of brain metastases in
women include: diagnosis of breast cancer at a younger age, tumors that are large or high
grade, presence of lymph node metastases, and certain subtypes of breast cancer. The
subtypes that have been shown to preferentially metastasize to the brain include estrogenreceptor negative, estrogen, progesterone, and HER2 receptor negative (triple negative), and
HER2+ breast cancers [3]. Survival for patients that have developed brain metastases is low,
ranging from 2 to 16 months after diagnosis.
Current treatment strategies for breast cancer brain metastases (BCBM) include surgery,
whole brain radiation or stereotactic radiosurgery, chemotherapy, and biological therapy [3].
Although these methods increase survival, the prognosis for patients with metastatic breast
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cancer, especially those with brain metastases, remains poor. The treatment of brain
metastases is especially challenging due to the number and location of secondary tumors,
performance status of the patient, and the biological subtype of the primary breast cancer
[12]. Many chemotherapeutic agents commonly used to treat primary breast cancer are
unable to penetrate the blood-brain barrier (BBB), which is a highly selective cellular barrier
that acts as a gatekeeper for solutes to enter the brain. In addition to keeping unwanted
physiologic substances out of the brain, it also prevents many chemotherapeutic agents from
reaching therapeutic concentrations within the brain, leading to potential resistance [13].

Author Manuscript

The incidence of brain metastases of breast cancer is increasing. Since 1979, the frequency
of stage IV breast cancer has increased from 10% in 1979 to 24%. [3]. Today, more brain
metastases are detected and diagnosed due to advanced imaging techniques. Although more
advanced and efficacious therapies are allowing patients to live longer, the increase in
survival has also increased the probability that primary cancer will metastasize to the brain
[3]. The increasing rate of brain metastases necessitates the development of novel treatment
strategies, which will be highlighted in this review.

2. Physiology / Pathology
2.1 Blood-Brain Barrier

Author Manuscript
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Blood vessels, which deliver blood from the heart to different organs, have different
properties to meet the requirements of the particular organ or tissue they vascularize [14].
Neurons of the brain communicate by chemical and electrical signals, which give rise to
their function. For these signals to be reliable and reproducible, the ionic concentration of
the tissue has to be constant to maintain homeostasis [15]. The microvasculature of the brain
plays an important role in regulating the entry of any solute into the brain parenchyma and
undisrupted function is required to maintain homoeostasis for proper neuronal function [15].
This unique property of brain microvasculature is described as the blood-brain barrier
(Figure 2A). Continuous, non-fenestrated capillaries form the BBB, in which endothelial
cells are attached together by tight junction protein complexes including claudins, occludins,
and intercellular adhesion molecules. These junctional components restrict the paracellular
diffusion of solutes [16, 17]. The brain endothelial cells also restrict vesicle mediated
transcellular movement more so than endothelial cells in the periphery [18]. Surrounded by
pericytes on the abluminal side, these cells have contractile proteins that regulate the
diameter of the capillary [19]. Astrocytic foot processes also cover microvasculature,
providing a link between neurons and blood vessels. Through this cellular link, astrocytes
mediate blood flow in accordance with neuronal activity [20, 21]. Astrocytes play an
important role in the formation of the BBB, and factors secreted by astrocytes play an
important role in BBB function [22]. In addition to the physical barrier properties of brain
capillaries, a great number of chemical barriers also exist in the BBB. Efflux transporters
including p-glycoprotein, the breast cancer resistance protein, and the family of multi-drug
resistance proteins are expressed on brain endothelium, which limit lipophilic solutes form
entering the brain [23, 24]. Enzymes secreted by the BBB (e.g., phosphatases) inactivate
larger molecules including peptides and neuropeptides, preventing their passing through the
BBB [25, 26].
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The BBB provides a stable and partially sequestered environment for neuronal activity by
means of ion regulation. Ion concentrations are kept relatively constant despite the changes
in plasma ion concentration due to acute or chronic changes in conditions [27–29]. The BBB
also separates central neurotransmitters from peripheral neurotransmitters. For example, the
peripheral neuroexcitatory amino acid glutamate is present at high concentrations in
peripheral blood and would cause permanent neurotoxic damage if allowed to enter the brain
[30]. Macromolecules like albumin, pro-thrombin, and plasminogen may initiate apoptosis
and are detrimental to central nervous system, but are restricted by the BBB [31, 32]. Aside
from restricting potentially toxic substances, the BBB also plays an important role in
regulating nutrition to the brain. Specific transport systems are in place for essential watersoluble nutrients [30]. Many pathways regulate angiogenesis and vasculogenesis, including
vascular endothelial growth factor (VEGF) and its receptors (VEGFR). Notch signaling also
plays an important role in regulating endothelial cell functions [33, 34].
While the BBB helps maintain homeostasis to support proper brain function, it also restricts
delivery of many drugs, including chemotherapy, to the central nervous system (CNS) [35].
Agents such as paclitaxel and doxorubicin are significantly subjected to efflux transport
mechanisms present at the BBB [36, 37], prompting development of analogues that can
circumvent the BBB and enter brain tissue [38].
2.3 Blood-Tumor Barrier

Author Manuscript

Once metastatic lesions begin to develop in the brain, BBB integrity is lost and the resulting
tumor microvasculature is often referred to as the blood-tumor-barrier (BTB) (Figure 2B)
[13]. As metastases grow, they promote the growth of new blood vessels via angiogenesis.
These new blood vessels lack tight junctions and proper astrocytic contact. As a result the
BTB has increased permeability and reduced blood flow [39–41]. In addition, the angiogenic
vessels have fenestrations, which increase permeability through paracellular pathways [42,
43], allowing normally regulated substances to freely enter the tumor and its
microenvironment.

Author Manuscript

However, BTB permeability is not homogenous from tumor to tumor or even within the
metastatic lesion [44]. Significant heterogeneity exists within and between tumors based on
findings from preclinical breast cancer brain metastases models [13, 45]. Brain metastases
become hypoxic as they grow beyond their blood supply. To meet their oxygen and nutrition
requirements, tumor cells secrete vascular endothelial growth factor (VEGF) to initiate the
process of new blood vessel formation [46]. VEGF secretion is associated with increased
turnover of endothelial cells leading to increased permeability [46]. Angiogenesis is a
dynamic process, to which the heterogeneity of BTB permeability between tumors can be
attributed [47, 48].
A multitude of factors exist that make treatment of BCBM difficult. These factors can be
anatomical or tumor-related. The region around the tumor, called the tumor
microenvironment, has physiological conditions that vary from the normal tissue physiology.
One such difference is hypoxia. Hypoxia induces resistance to drug and radiation therapy
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[49]. A few conventional chemotherapy drugs such as bleomycin, etoposide, and
cyclophosphamide, require oxygen to exert their cytotoxic effects [50]. Thus, under hypoxic
conditions, these drugs fail to have an optimal cytotoxic effect leading to tumor resistance.
2.4 Effects of the BBB and BTB on drug therapy

Author Manuscript

Although lipophilic drugs have higher tendency to cross the BBB, many drugs achieving this
feat are subject to efflux by the efflux pumps of the BBB. The primary efflux transporters
belong to the ATP-binding cassette transporter family. Found on the luminal side of the
BBB, these include the P-glycoprotein (P-gp), breast cancer resistance protein, and the
multi-drug resistance protein [51]. Amongst them, the P-gp, present on both luminal and
abluminal side, serves to remove a wide variety of substrates including chemotherapeutic
drugs such as paclitaxel. The breast cancer resistance protein efflux transporter is also an
important contributing factor in chemotherapy resistance. The BBB is dynamic in nature,
and changes are seen in its integrity in different disease states, including metastatic cancer
[52]. As stated previously the BTB has a higher permeability to chemotherapy as compared
to the intact BBB; however therapeutic concentrations of drug are still unable to get across
to the desired site. To add to the challenge, the BTB is highly variable in nature, which leads
to variable drug concentrations reaching the target [53]. Chemotherapeutic drugs paclitaxel
and doxorubicin were found to penetrate the BTB more easily compared to BBB in a brain
metastatic mouse model of breast cancer; however, the drug concentrations in tumor were
sub-therapeutic and non-uniform [13, 54]. Circumventing the BBB, BTB, and the efflux
processes remain the ultimate challenge for the effective therapy of brain metastases.

3. Subsets of Breast Cancer Brain Metastases
Author Manuscript

3.1 Hormone receptor-positive

Author Manuscript

Hormone receptor-positive (HR+) breast cancer is a subtype of breast cancer that expresses
estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor
receptor 2 (HER2). These types of tumors respond differently to treatment and confer a
variety of prognoses [55]. Although PR are typically regulated by ER, they can act
independently at times, creating the three types of HR+ BC: ER positive/PR positive, ER
positive/PR negative, and ER negative/PR positive [55–57]. ER+/PR+ and ER+/PR− are more
common and generally easier to treat than ER−/PR+ due to the presence of ER, which is the
target for most HR+ BC therapies [55]. Furthermore, ER−/PR+ BC displays greater growth
rates and are less responsive to endocrine therapy related to metastatic BC [56, 57]. The
estrogen and progesterone signaling pathways are very similar representations of the typical
steroid mechanism [55]. Although there are different types of ER and PR in cells, the main
targets of medication are the nuclear transcription factors (i.e. ERα) responsible for cellular
growth and proliferation [55, 57]. The endogenous hormones freely diffuse through the cell
membrane to their respective protein receptors, which dimerize upon binding their hormone
and translocate into the nucleus to bind DNA and activate transcription [55]. The HR+ BC
subtypes tend to be more treatable than other BC subtypes due to the significant
effectiveness of endocrine therapy on ER+BC [55].
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There are no chemotherapeutic agents or regimens specifically approved for hormone
receptor-positive BCBM, however many are being investigated through clinical trials [58].
Multiple studies have demonstrated that the luminal subtypes of breast cancer (luminal A
and luminal B) are associated with decreased likelihood of brain metastasis [59–61].
However, some chemotherapeutic research is being done for the rare cases when hormone
receptor positive breast cancer does metastasize to the brain. In 1991, Lien et al. determined
tamoxifen and its metabolites achieved 46 times higher concentrations in brain tissue
compared to serum levels [62]. Then in 2006, a phase I trial was conducted with 24 BCBM
patients receiving a combination of capecitabine and temozolomide [63]. The study reported
one complete response and three partial responses warranting the need for further research
regarding this therapy [63]. Three years later a retrospective study examined five BCBM
patients who were treated concurrently with capecitabine and WBRT [64]. Of the five, one
achieved a complete response, two achieved partial responses, one had stable disease, and
one patient was deceased [64]. Three years after the previous study, Addeo et al. conducted a
trial with the combination of vinorelbine, temozolomide, and WBRT in 36 patients [65].
This study reported three complete and 16 partial responses, with a PFS and OS of eight and
11 months, respectively [65]. After another three-year period, eribulin was compared to
capecitabine in the treatment of HR+ MBC with metastasis to the brain. All three selected
patients from the study who received eribulin displayed brain lesion shrinkage during the
study and fewer total patients developed new BCBM with eribulin than with capecitabine
[66]. This study notes that eribulin does not cross a healthy BBB but capecitabine may [66].
That same year, Niravath et al. concluded that concomitant treatment of capecitabine and
WBRT followed by capecitabine and sunitinib did not extend PFS and was associated with
significant toxicity [67]. Furthermore, in 2015, a prospective study comparing BCBM versus
serum concentrations for capecitabine and lapatinib concluded that both drugs penetrate
BCBM to a significant albeit variable degree [68]. The American Society of Clinical
Oncology recommends endocrine therapy as the initial treatment for HR+ metastatic breast
cancer, with aromatase inhibitors being the first-line [69]. Fulvestrant or human epidermal
growth factor receptor 2 (HER2)-targeted therapies can be added to the first-line treatment if
the patient has not had prior exposure to adjuvant endocrine therapy or has HR+ and HER2+
metastatic BC, but it is not recommended to combine targeted endocrine therapy and
nonspecific chemotherapy [69]. Table 1 lists the results of clinical trials involving HR+
BCBM.
3.3 Novel Therapy for Hormone Positive Brain Metastases

Author Manuscript

There are only a few clinical trials specifically involving HR+ BCBM. The majority of trials
allow for participant enrollment if patients have been previously treated with radiation,
surgery, or previous chemotherapy at least 2 weeks to 3 months prior to enrollment, with
image-confirmed non-progression of brain lesions, and stability of disease without
corticosteroid or anti-epileptic use. A compilation of ongoing and initiated clinical trials for
HR+ BCBM is provided in Table 3. An illustration of overall mechanisms is provided in
Figure 3.
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3.3.1 CDK4/6 inhibitors—Three cyclin-dependent kinase CDK-4 and -6 (CDK 4/6)
inhibitors are being evaluated for their effects in treating hormone-positive BCBM:
abemaciclib, palbociclib, and ribociclib. Abemaciclib has proved to be a safe and effective
treatment for HR+/HER2− metastatic breast cancer in three separate MONARCH trials, the
second of which earned the drug approval from the FDA [70–73]. However, women with
CNS metastases were excluded from all three trials, raising the question of abemaciclib’s
efficacy for the treatment of BCBM. Subsequently, there are a few ongoing trials of
abemaciclib that include patients with HR+ BCBM. The first is a Phase II study specifically
looking at abemaciclib’s safety and effectiveness in participants with BM from non-small
cell lung cancer, melanoma, and HR+ BC (NCT02308020). The monarcHER trial is a Phase
II study evaluating the effectiveness of abemaciclib and trastuzumab with/without fulvestrant
in the BCBM setting (NCT02675231). Lastly, there is an expanded access study for HR+/
HER2− metastatic BC to be treated by abemaciclib after disease progression on prior
therapies (NCT02792725).

Author Manuscript

Palbociclib is another CDK4/6-specific inhibitor under investigation in combination with
other agents for the treatment of BCBM. It is being explored as monotherapy in the Phase III
PATINA study including HR+ BCBM patients (NCT02947685). Palbociclib is also being
studied in combination with aromatase inhibitors such as letrozole (NCT02600923),
selective estrogen receptor modulators such as bazedoxifene and tamoxifen (NCT02448771,
NCT02668666), and selective estrogen receptor degraders such as fulvestrant
(NCT02738866). Other combinations with palbociclib include everolimus and exemustane
(NCT02871791), exemustane and leuprolide (NCT02592746), fulvestrant or tamoxifen
(NCT02384239), and the PI3K inhibitors taselisib or pictilisib (NCT02389842). In the
PALINA trial, the combination of palbociclib and either letrozole or fulvestrant is being
investigated in treating stable HR+/HER2− BCBM participants that self-identify as black,
African, or African-American [NCT02692755).
Ribociclib (LEE011) is being explored in combination with many estrogenic pathway
inhibitors in the treatment of BCBM. A phase 3 trial is looking at ribociclib efficacy in
combination with letrozole (NCT03096847). A Phase 1 trial is evaluating ribociclib and
letrozole along with alepelsib (NCT01872260). Similar to the phase 3 MONALEESA-3
trial, ribociclib is combined with fulvestrant for HR+/HER2− BCBM (NCT02422615) or
following disease progression on prior treatment with an aromatase inhibitor or other CDK
4/6 inhibitor (NCT02632045). In the Phase 1 TEEL study, ribociclib is combined with
tamoxifen with and without goserelin in HR+/HER2− metastatic breast cancer patients who
may also have brain metastases (NCT02586675).
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3.3.2 PI3K inhibitors—Three phosphoinositide 3-kinase (PI3K) inhibitors are being
evaluated in combination with anti-estrogenic agents for their efficacy in treating hormonepositive BCBM: alpelisib, buparlisib, and dactolisib. In the SOLAR-1 Phase 3 trial, the PI3K
inhibitor alpelisib (BYL719) is coadministered with fulvestrant for participants with
aromatase inhibitor-refractory HR+/HER2− BCBM (NCT02437318). Similarly, alpelisib is
being explored in combination with letrozole for participants with HR+/HER2− nonsymptomatic BCBM in a Phase I study (NCT01791478).
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In the BELLE-4 study, buparlisib was paired with paclitaxel in the treatment of
asymptomatic HER2− metastatic BCBM. Though overall results were posted for 338
patients, no specific results were posted for BM patients (NCT01572727). This trial was
meant to be a Phase II study followed by a Phase III, but was ended after the second phase
due to pre-defined futility criteria as there was no improvement in progression free survival
[74]. Subsequently, buparlisib was paired with fulvestrant in two separate Phase 3 studies,
BELLE-2 and BELLE-3, evaluating its effectiveness in treating asymptomatic HR+/HER2−
BCBM after disease progression on an aromatase inhibitor (BELLE-2) or an mTOR
inhibitor (BELLE-3) (NCT01610284, NCT01633060). In a second experimental group of
the Phase I B-YOND study, the PI3K inhibitor buparlisib will be combined with tamoxifen
and goserelin (NCT02058381). Although no results have been posted, buparlisib completed
a Phase I study in combination with letrozole in which BCBM patients were included
(NCT01248494). In the Phase II STAR Cape study, buparlisib will be combined with
capecitabine to treat any type of BCBM, though the HER2+ subset is also receiving
trastuzumab (NCT02000882).
In a second experimental group from a previously mentioned completed phase 1 study,
dactolisib will be combined with letrozole for BCBM participants (NCT01248494).
3.3.3 HDAC inhibitor—In a completed phase 1 study, entinostat (SNDX-275) was
combined with erlotinib and exemestane for patients with HR+ metastatic BC including their
brain metastases, but no results are posted (NCT01594398). Entinostat is being combined
with exemestane in an upcoming Phase 1 trial for patients with similar criteria
(NCT02833155).

Author Manuscript

3.3.4 mTOR inhibitors—In two ongoing Phase 1 trials, everolimus is being explored in
combination with letrozole and trastuzumab for HR+ BCBM patients (NCT02152943,
NCT02269670). In a Phase 2 study, everolimus was combined with an anti-estrogen drug
using similar criteria as Phase 1 trials (NCT02291913). In the Phase 2 LEO trial, everolimus
is combined with letrozole and leuprorelin following disease progression with tamoxifen
with or without a GnRH agonist (NCT02344550). In the Phase 3 MAIN-A study, everolimus
is combined with an aromatase inhibitor as part of a maintenance regimen for HR+/HER2−
BCBM following treatment with one line of chemotherapy (NCT02511639).
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3.3.5 Estrogen pathway antagonists—In addition to the trials listed above, anastrozole
is being combined with the CDK4/6 inhibitor palbociclib in a Phase 2 study (02942355). In
the phase 3 FEVEX study, fulvestrant is followed by exemestane and everolimus in the
setting of symptomatic BM (NCT02404051). In a phase 2 study, fulvestrant is being
investigated with and without ganetespib (NCT01560416). Fulvestrant is being utilized with/
without lapatinib in a Phase 3 study (NCT00390455). Alisertib (MLN8237), an Aurora A
kinase inhibitor, proved to be ineffective in Phase III trials, but is now being combined with
fulvestrant in a Phase I study (NCT02219789).
GDC-0810, a selective estrogen receptor degrader, is being tested in a Phase 1 and 2 study as
monotherapy and in combination with palbociclib and/or a luteinizing hormone-releasing
hormone agonist (NCT01823835). Elacestrant (RAD-1901), another selective estrogen
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receptor modulator, is in two Phase 1 studies for HR+ BCBM patients that have progressed
on at least 1 line of hormone therapy (NCT02650817, NCT02338349). Z-Endoxifen is being
utilized in a Phase 1 study on participants with HR+ solid tumors and those with metastatic
disease must have had at least one prior chemotherapy treatment (NCT01273168).
3.3.6 VEGF inhibitors—Cabozantinib, an inhibitor of c-Met and VEGFR2, is being
trialed with and without trastuzumab in BCBM patients in a Phase II study that spans across
HR+, HER2+, and triple-negative subtypes (NCT02260531). In another Phase II study,
cabozantinib is combined with fulvestrant (NCT01441947). Lenvatinib, a tyrosine kinase
inhibitor against VEGFR receptors, is being combined with letrozole in a phase 1 and 2
study on asymptomatic HR+ BCBM (NCT02562118).
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3.3.7 Insulin-like growth factor receptor antibodies—Xentuzumab (BI836845), an
insulin-like growth factor receptor 1 antibody, and abemaciclib are being investigated with
and without hormonal therapy (NCT03099174). The insulin-like growth factor-1 inhibitor
BMS-754807 completed a Phase II study where it was tried with and without letrozole, but
results have not been published (NCT01225172).
3.4 Triple Negative
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The absence of ER, PR, and HER2 receptors (ER−, PR−, HER2−) in breast cancer cells is
termed triple negative or the basal subtype. Triple negative breast cancer (TNBC) is
aggressive and tends to affect younger women. Due to the lack of targeting options, TNBC
often has a high rate of recurrence and a worse prognosis than other breast cancer subtypes.
[75–77] TNBC make up approximately 30% of all BCBM, with approximately 40% of
metastatic TNBC eventually developing brain metastases. [78] As such, therapy is primarily
with systemic cytotoxic therapy. TNBC typically have an initial response to chemotherapy
that often relapses to cause large numbers of chemoresistant metastases. [79]
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3.4.1 Systemic Chemotherapy—Chemotherapy clinical trials have typically excluded
patients with brain metastases for a variety of reasons, including limited penetration of
agents through the BBB and BTB, the lack of a convenient modality for tumor burden
monitoring, and poor overall survival prognoses leading to negative outcomes for patients
[80]. Some of the earliest published work in chemotherapy for brain tumors began in the
1950s and 1960s, focusing on use of systemic agents such as methotrexate, thioTEPA,
nitrosoureas, and vinca alkaloids. [81–84] Kofman et al noted the use of prednisolone to
reduce neurological symptoms in 1957. [85] Though the chemotherapy field has advanced, a
regimen specific for the treatment of BCBM has yet to be approved and ratified by the Food
and Drug Administration (FDA) or national and international cancer organizations. Systemic
cytotoxic therapy including taxanes (docetaxel, paclitaxel), anthracyclines (doxorubicin),
platinum compounds (cisplatin), and alkylating agents (cyclophosphamide) in combination
with other agents have shown some efficacy in small studies. [86–89] The rise of novel
dosage forms, immunotherapy, and small molecule inhibitors has pushed the envelope of
treatment expectations and produced trials focusing specifically on BCBM.
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3.4.2 Traditional Chemotherapy—Various combinations of cisplatin, etoposide,
doxorubicin, 5-fluorouracil, methotrexate, vincristine, teniposide, lomustine, irinotecan,
gemcitabine, paclitaxel, and temozolomide have been trialed in BCBM patients. Of these
combinations, cisplatin-etoposide [90] alone or pretreated with bevacizumab [91], cisplatincyclophosphamide [92], cisplatin-vinorelbine [93], and cisplatin-gemcitabine [94] showed
significant efficacy. Full descriptions of nonspecific chemotherapeutic regimens and
descriptions are provided in Table 3.
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Based on clinical trials, cisplatin has become the backbone for treating both primary BC as
well as BM. Cisplatin, bevacizumab, and etoposide were combined for a Phase II trial of 8
BCBM patients in Taiwan, showing effect in 5 [95]. Cisplatin is being combined with
veliparib, a PARP-inhibitor, for treating triple-negative and BRCA-mutated BC and
associated BM (NCT02595905). As a single agent, temozolomide has been explored to treat
brain metastases of breast cancer, lung cancer, and melanoma (NCT00831545) Eribulin,
though not a targeted agent, is noted for its potential response in both triple-negative and
HER2+ patients, and is being studied in a Phase II trial in the treatment of HER2+ BCBM
(NCT02581839). Figure 3 illustrates the mechanism of traditional chemotherapy.
3.5 HER2+
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HER2 overexpression is found in 20-25% of all breast cancer cases [96]. As a plasma
membrane-bound receptor tyrosine kinase (RTK), HER2 upregulation increases signaling
from the extracellular environment for promotion of cellular survival and proliferation
through a variety of downstream effectors [97]. Significantly, the HER2+ and TNBC
subtypes have been shown to metastasize to the brain at higher rates than other BC subtypes
[98–101]. The enhanced extracranial systemic management of HER2+ metastatic BC with
HER2–therapies trastuzumab and pertuzumab in addition to chemotherapy has contributed
to the increased incidence of BM in this group [97]. One of the major pathways involved in
the HER2–targeted therapy resistance essential to survival of HER2+ BC cells that colonize
the brain is that of PI3K. The PI3K pathway that transmits signals of cell cycle progression
and survival to the central circuitry of the cell is over-activated via the mechanisms of PTEN
loss and acquisition of activating mutations in the PI3K gene in trastuzumab-resistant BC
[102–104].
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3.5.1 HER2+ Therapy—Treatment of HER2+ metastatic breast cancer with pHER2targeted monoclonal antibody rhuMAb was first shown to have efficacy in patients who had
received extensive prior chemotherapy in a Phase II study conducted by Baselga et al. in
1996 [105]. Two years later a phase 2 study showed that the combination of rhuMAb and
cisplatin produced higher clinical response rates in metastatic BC patients than either as a
monotherapy [106]. Just a few years later in 2001, Slamon et al. demonstrated that HER2–
targeted monoclonal antibody trastuzumab in addition to either an anthracycline and
cyclophosphamide combination, paclitaxel, or chemotherapy compared to each alone
produced significantly longer progression-free survival (PFS) [107]. Recently in 2015,
Swain et al. reported the most recent analysis of the CLEOPATRA trial [77] in which
pertuzumab, a monoclonal antibody targeting a different epitope on the extracellular portion
of HER2 than trastuzumab, was added to trastuzumab and docetaxel for the treatment of
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metastatic BC [108]. The addition of pertuzumab improved overall survival (OS) by 15.7
months to 56.5 months in treatment-naive patients, supporting the use of this triplet therapy
in the clinic [108].
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The increasing incidence of HER2+ BC metastasizing to the brain necessitates an intense
focus on the treatment of these lesions. According to the American Society of Clinical
Oncology 2014 Clinical Practice Guidelines for the treatment of HER2+ metastatic BC and
BM, patients should receive local therapies including surgery, whole-brain radiotherapy, and
stereotactic radiosurgery, and systemic therapy if indicated [109]. Many groups have
investigated the roles of systemic chemotherapy, targeted therapy, immunotherapy, or a
combination of these for the treatment of HER2+ BCBM. The registHER study found that
HER2+ BCBM patients treated with chemotherapy vs. no chemotherapy had greater OS
(16.4 vs. 3.7 months) and patients treated with trastuzumab had greater OS (17.5 vs. 3.8
months) [110]. Multiple studies have shown patients with HER2+ metastatic BC with BM
who received trastuzumab have improved survival due to better extracranial systemic
management of HER2+ metastatic BC. Unfortunately, trastuzumab is less effective in
controlling HER2+ CNS metastases [111–113]. Later it was found that the combination of
lapatinib and capecitabine extended OS for HER2+ BCBM patients compared to
trastuzumab alone [114, 115]. Further, Phase 2 results from the LANDSCAPE study
indicated that combining lapatinib and capecitabine for first-line treatment of HER2+ BCBM
showed activity by providing objective CNS responses in 65.9% of patients [116]. Most
recently, ado-trastuzumab emtansine (T-DM1), a trastuzumab molecule conjugated to a
cytotoxic microtubule-destabilizing agent, was associated with longer OS when compared to
the combination of lapatinib and capecitabine [117]. T-DM1 significantly improved OS vs.
treatment of physician’s choice in HER2+ metastatic breast cancer following two or more
HER2-targeted treatment regimens in the phase 3 open-label TH3RESA trial [118]. To
support the efficacy of T-DM1 in the treatment of HER2+ BCBM, a handful of small trials
and case studies have reported promising results [119–123]. Perhaps the most encouraging
results to date are those from the ongoing phase 3b KAMILLA study of T-DM1 in HER2+
BCBM patients which show that T-DM1 treatment decreases the size of brain target lesions
in 84 of 126 patients with measurable CNS lesions [124]. Table 4 lists results of completed
HER2+ BCBM clinical trials.

Author Manuscript

3.5.2 Novel Chemotherapy for HER2+ Brain Metastases—The future of
pharmacological intervention for the treatment of HER2+ BCBM looks bright, however
many challenges remain. These include determining the precise BTB permeability of TDM1 in HER2+ BCBM and to ascertain the mechanistic contributions of the trastuzumab
molecule and DM1 molecule in conferring the cytotoxic actions of T-DM1 in the brain
TME. The concurrent use of radiosurgery and T-DM1 elicited a 75% response rate in a small
group of patients with HER2+ BCBM (n=4): one complete response, one partial response,
one stable disease, and one progression [125]. This report is supported by mechanistic data
showing that T-DM1 provides potent and tumor selective radiosensitization [126]. The
rational combination of T-DM1 with targeted therapies that inhibit over-activated pathways
in HER2+ metastatic BC has also been an area of interest. A phase 1 study of T-DM1 in
combination with alpelisib (BYL-719), an oral PI3K inhibitor, showed that the combination
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was safe and provided significant anti-tumor activity in metastatic BC patients previously
treated with trastuzumab and taxane therapy [127]. It will be of great interest to determine
whether combining T-DM1 with BBB-permeable targeted therapies that inhibit overactivated pathways in HER2+ BCBM confers greater benefit than T-DM1 alone. A phase 1b
trial combining trastuzumab with PI3K inhibitor, buparlisib, showed an impressive disease
control rate (75%) in HER2+ metastatic BC and supported the continuation to a phase 1b/2
trial including BM patients (NCT01132664) [128]. While this trial was ultimately
terminated, many of the preclinical and clinical studies referenced above support a trial
combining T-DM1 with a PI3K inhibitor (alpelisib or BBB-permeable buparlisib) for the
treatment of HER2+ BCBM patients.
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There are varieties of planned, recruiting, and active clinical trials for the treatment of
HER2+ BCBM patients. The combination of everolimus, trastuzumab, and vinorelbine in
treating this cohort is currently being investigated (NCT01305941). Others are seeking to
determine whether T-DM1 in combination with metronomic temozolomide compared to TDM1 alone confers secondary prevention of HER2+ BCBM following stereotactic
radiosurgery (NCT03190967). An ongoing phase II study is looking at the efficacy of
lapatinib for the treatment of HER2+ BCBM that have progressed following radiation
treatment using whole brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) to the
brain (NCT00263588). A planned phase II study by the Jules Bordet Institute will determine
whether T-DM1 (Kadcyla) is effective in treating HER2+ BCBM (NCT03203616). To test
whether HER2-targeted therapy resistance is a factor in the relative ineffectiveness of
trastuzumab and pertuzumab for the treatment of HER2+ BCBM, a phase I trial will assess
the combination in patients with new untreated asymptomatic or low symptomatic HER2+
BCBM (NCT02598427). A phase I study of T-DM1 in combination with sequential whole
brain radiotherapy was competed, however no results have been posted yet (NCT02135159).
Another phase I study is observing the effect of ARRY-380 (HER2-targeted agent that
appears to have some brain penetration) in combination with trastuzumab for the treatment
of HER2+ BCBM (NCT01921335). A phase I study combining lapatinib, WBRT, and
trastuzumab reported a median PFS of 4.8 months and median OS of 18 months in HER2+
BCBM patients (NCT00470847). The combination of neratinib (HKI-272) and capecitabine
is currently being used in a phase II study at Dana-Farber Cancer Institute for the treatment
of HER2+ BCBM (NCT01494662). The phase I LAPTEM trial combined lapatinib and
temozolomide for the treatment of progressive HER2+ BCBM, however no results have been
posted (NCT00614978). A phase II study of local therapy (SRS and/or neurosurgery) is
planned for the treatment of up to 5 BMs in individual HER2+ BC patients (NCT02898727).
The phase II Lux-Breast 3 study demonstrated that afatinib alone or in combination with
vinorelbine did not produce better outcomes than treatment of physician’s choice (TPC)
(NCT01441596). A phase II trial sponsored by Northwestern University is recruiting
patients with HER2+ BCBM to be treated with a combination of palbociclib and
trastuzumab (NCT02774681). Another phase II study by the National Cancer Institute (NCI)
is recruiting patients to explore the combination of WBRS/SRC in combination with
lapatinib for the treatment of HER2+ BCBM (NCT01622868). Yet another phase II study is
recruiting patients with HER2+ BCBM to test the effectiveness of cabozantinib +/−
trastuzumab (NCT02260531). Lastly, the combination of tucatinib, capecitabine, and
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trastuzumab will be compared to placebo, capecitabine, and trastuzumab in the phase 2
HER2CLIMB trial (NCT02614794). Table 5 outlines in-progress and upcoming HER2+
trials that include BM patients. Figure 3 illustrates mechanism of HER2+ therapeutics.

4. Formulations involved in treating brain metastases
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The BBB provides considerable resistance to chemotherapeutic agents. Specific
physicochemical properties allow drugs access into the brain. General characteristics that
promote BBB permeation have been summarized to have an optimal molecular weight
400-600 Da, higher lipophilicity and lower participation in hydrogen bonding. In an attempt
to increase BBB permeability, chemical modification of drug molecules by charge reduction
and addition of lipophilic moieties is a common approach. The BBB itself can be chemically
targeted so that it transiently allows the passage of therapy across. Compounds such as
bradykinin [129] and its synthetic analogs [130], interleukin-2 [131], and leukotriene C4
[132] have been used to open tight junctions as well as osmotic agents such as mannitol.
However, this approach comes with the risk of adverse and of infections due to a
compromised BBB. Adenosine receptor agonists using a dendrimer-based delivery have also
been used to briefly open the BBB, reducing complications [133].
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Nanotechnology has become one of the defining standards in the development of “novel”
therapeutic agents. Use of nanometer sized carriers for targeted delivery of
chemotherapeutic drugs to brain metastases is one of the most commonly investigated
approaches. Polymeric nanoparticles, solid-lipid nanoparticles, micelles, and liposomes are
some of the delivery systems that can be used to achieve drug entry through the BBB. These
novel drug delivery systems can be used to achieve spatial (site-specific) as well as temporal
(time-dependent) control over treatment of brain metastases of breast cancer. Active
targeting of the drugs can be achieved by delivering them via multifunctional nanoparticles.
These systems have tumor specific moieties on their surface, which directs the carrier to the
tumor site, where the drug is released. The main hypothesized advantage of using
nanocarriers for cancer therapy is the Enhanced Permeation and Retention (EPR) effect.
This concept was first laid down by Matsumura and Maeda, when they studied the tumor
accumulation of a polymer conjugated protein neocarzinostatin, and a series of radiolabeled
proteins of varying sizes [134]. Macromolecules tested were found to have a greater
accumulation and longer retention in tumor tissue, as a function of their size. The observed
phenomenon was attributed to twin effects [135].
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Tumor vasculature is leaky due to rapid angiogenesis and elevated levels of vascular
permeability factors, facilitating the permeation of macromolecules into the tumor tissue.
Additionally, the absence of proper lymphatic drainage supports longer retention of
chemotherapy at the tumor site. This effect can be applicable to drug delivery systems such
as nanoparticles, micelles, and liposomes [136]. The EPR effect is attributed to liposomal
and nanoparticulate formulations showing tumor site accumulation. Unfortunately, adequate
evidence does not exist for the EPR phenomenon. Only one clinical study showed
accumulation of radiolabeled PEGylated liposomes in tumor tissues, an indication of the
EPR effect [137].
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A mathematical model to quantify the EPR effect was developed based on pharmacokinetic
data from the clinical trials of the FDA approved PEGylated liposomal formulation of
doxorubicin, Doxil® [138]. This pharmacokinetic model considered the tumor as a separate
compartment, and introduced rate constants for extravasation, as well as intravasation. The
tumor accumulation of Doxil was significantly higher compared to that of conventional
doxorubicin. It has been determined that drug delivery systems should preferably be
biocompatible materials, a size of at least 40 kDa or more for the EPR effect to be applicable
[139], with the caveat that heterogeneity within the tumor tissue, and among tumor types,
makes the EPR effect variable. Some of the parameters responsible for variable EPR effects
include low systolic blood pressure, hypoxia, presence of emboli, and vascular density
[140]. This phenomenon can be erratic with micellar and liposomal drug delivery systems,
as they need to maintain system stability until they reach the site of action. The EPR effect
has been used to predict therapeutic outcomes, but is not a reliable marker [140].
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The therapeutic effect of the drug is a downstream effect that is dependent of other factors
such as drug release and drug uptake. To make EPR more uniform, its augmentation has
been described in rodents as well as humans using elevation of blood pressure [141]. Due to
its heterogeneity, the EPR effect has been unsuccessful in a clinical setting, a stark contrast
to its efficiency in pre-clinical murine models [142]. Better characterization of the EPR
effect is required to create uniformity and reliability in clinical scenarios. Regardless of EPR
in humans, nanoparticle based drug delivery systems still have relevance in terms of
reducing the toxicity of chemotherapy drugs, localized delivery and imaging of tumor
microenvironment [142].

5. Drug delivery systems intended to target brain metastases
Author Manuscript

5.1 Liposomes
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Liposomes are a drug delivery vehicle that consists of a phospholipid bilayer containing an
inner, aqueous pocket. Hydrophilic drugs or imaging agents may be incorporated into the
aqueous compartment, or hydrophobic ones in the lipid bilayer [143]. There are multiple
types of liposome structures that may form when phospholipids are suspended in aqueous
solution, including micelles and multilamellar or unilamellar vesicles. These liposomes may
be generated via multiple methods; the most common being thin lipid film hydration.
Freeze-thaw cycles, sonication, and extrusion through filters are additional procedures which
may be used to control the vesicle type and size distribution [144]. Typically, liposomes used
for clinical drug delivery are constructed from endogenous lipids such as cholesterol or their
synthetic derivatives, have a size on the order of 100 nm diameter, and are unilamellar in
structure [145, 146].
The use of liposomes provides an opportunity for targeted drug delivery. Targeting ligands
such as homing peptides and whole antibodies or their fragments, may be inserted on the
surface of the liposomes [147]. This targeting confers liposomes the ability to potentially
cross the BBB by adsorptive-mediated transcytosis (AMT) and receptor-mediated
transcytosis [148]. AMT is a nonspecific mechanism in which the cationized surface of
liposomes may interact with the anionic glycocalyx, stimulating their endocytosis and
transport to the abluminal portion of the endothelial cell where they are exocytosed into the
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interstitial fluid of the CNS [149]. Receptor-mediated transcytosis works through a similar
mechanism whereby receptors on the luminal surface of the endothelium, such as the
insulin, transferrin, and LDL receptors, may bind to liposomes which have been labeled with
ligands or antibodies for these receptors [147–152]. These processes may result in three
different fates for the liposome: they may pass through the endothelial cell completely and
enter the brain, they may stay inside the endothelial cell, or they may be returned to the
lumen of the vessel. These transcytotic pathways of BBB penetrance are the predominant
pathways for liposomes because paracellular diffusion is limited by tight junctions and
particle size [152–158].
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One common problem with nanoparticle vehicles, including liposomes, is their rapid
clearance by the reticuloendothelial system. This problem is ameliorated in the case of
liposomes by incorporating PEG into the lipid membrane [159]. While PEGylation provides
more opportunities for attachment for targeting moieties and may reduce clearance,
immunogenicity, and antigenicity, it can have negative effects, such as the increased
accumulation in the skin, increasing the risk of developing hand-foot syndrome with some
formulations. Non-PEGylated liposome formulations have also been developed, which
overcome reticuloendothelial system clearance and immunogenicity [151].
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Preclinical data using a mouse model of brain metastases demonstrated a PEGylated
liposomal formulation of irinotecan (MM-398) greatly enhanced its cytotoxic effect
compared to conventional irinotecan [160]. Liposomal formulations of anthracyclines, such
as Doxil®, show improved efficacy and toxicity profiles in comparison to conventional
formulations [161]. Several drug formulations including liposomes have already received
FDA approval. These include liposomal preparations of cancer drugs such as doxorubicin
(Doxil®), daunorubicin (DaunoXome®), irinotecan (Onivyde®), and vincristine
(Marqibo®), which are being explored in the treatment of BCBM. Liposomal formulations
developed for brain metastases have yet to be approved, but clinical trials using glutathione
PEGylated liposomal doxorubicin (NCT01386580] and liposomal cytarabine
(NCT00992602) are underway.
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Doxil® is a marketed formulation of doxorubicin, delivered using PEGylated liposomes.
The addition of PEG imparts a ‘stealth’ feature to the nanosystem, by allowing it to avoid
premature clearance via the RES. A modified version of Doxil®, was developed with an
additional coating of glutathione [152]. Active transport of glutathione across the BBB
helped enhance doxorubicin accumulation at the metastatic sites, as well as prolong
circulation time. Doxorubicin bound to polysorbate 80-coated butyl cyanoacrylate
nanoparticles was found to cross the intact BBB and reach therapeutic levels in the rat brain
[162]. A multifunctional theranostic nanosystem was developed for the delivery of
doxorubicin and diagnostic agents for brain metastases [163]. The system consisted of a
terpolymer comprised of poly(methacrylic acid) and polysorbate 80 on a starch scaffold.
5.2 Conjugating nanoparticles
Housing therapeutics inside 10 nm to 100 nm carriers allow for smaller doses to be given
that simultaneously achieve similar or enhanced efficacy, a reduction in side-effect profile,
prolonged dosing intervals, and enhanced accumulation compared to their conventional
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chemotherapy counterpart [164]. The carriers are often pegylated liposomes as described
above, but conjugation to proteins such as transferrin or albumin are also used clinically.
Paclitaxel has been formulated as polyethoxylated albumin bound nanoparticles
(Abraxane®) and its published phase II [165] and phase III [166] clinical trials reported
significant anti-tumor activity compared to standard paclitaxel. It targets the tumor by
transcytosis, mediated by the albumin receptor (gp-60). The formulation, devoid of
Cremophor EL solvent, was found to be safer. Microemulsion derived nanoparticles of
paclitaxel have been prepared using cetyl alcohol and polysorbate as materials [167]. When
tested in a rat model, the drug was shown to have an increased brain uptake and toxicity
against P-gp expressing cancer cells, indicating a possible protection of paclitaxel from P-gp
mediated efflux. Nanoparticles can also be used to house genetic therapy. A Phase I trial of
nanoparticles housing the Rexin-G anti-cyclin G1 construct in the treatment of recurrent or
metastatic breast cancer was started in July 2007, but no study results are posted as of 2011
(NCT00505271).
Conjugation of chemotherapy to other small molecules allows for targeting. Preclinical
models of BCBM were found to have a prolonged survival when treated with
nanoconjugates of paclitaxel and hyaluronic acid [168]. This formulation exploited passive
diffusion across the BBB, and active tumor cell uptake due to the affinity of hyaluronic acid
for CD44 receptors. The active targeting was aimed at circumventing the P-gp efflux that is
observed with paclitaxel. Active targeting of mitoxantrone was achieved by targeting the
LDL receptor related protein using angiopeptide-2 ligand conjugated on the surface of fluid
membrane liposomes [153]. This formulation was found to have improved therapeutic
potential in experimental brain metastasis model of breast cancer.
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5.3 Pegylation
Polyethylene glycol (PEG) moiety attachment has been a frequent method employed by the
pharmaceutical industry for nearly four decades to improve the systemic circulation of
bioactive molecules with poor pharmacokinetic profiles [169]. PEGylation refers to the
covalent adherence of multiple linear or branched polyethylene glycol molecules to a drug
product [170]. PEGylation has been utilized in small molecules, liposomes, carbohydrates,
enzymes, nucleotides and other nanotherapeutic strategies [171–173]. The most common
molecule used during the PEGylating process is methoxy-polyethylene glycol (mPEG)
[170]. Much like liposomes, the EPR effect can be exploited in the cancer setting. Large
macromolecular therapies are able to passively enter tumors due to the presence of neoangiogenesis and degree of permeability within tumor vasculature [135].
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PEG is known to enhance the pharmacokinetics of poorly circulating chemotherapeutics. In
the case of the brain, PEG has been shown to increase the concentration of cytotoxic drugs
reaching brain tissue [152]. PEG is also shown to enhance the bioavailability of orally
available drugs by protecting them from catalytic degradation [174].
While PEGylation also reduces the toxicity profile of many chemotherapeutic agents [175,
176], this is not without its own drawbacks. After undergoing IV administration of
PEGylated nanomedicines and small molecules, clotting and clumping can occur, initiating a
cascade of detrimental side effects, such as embolism [177]. Hypersensitivity to PEGylated
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therapies is also an important concern. The complement activation cascade of the immune
system is thought to play a role in immunogenicity of PEG molecule, which may lead to
anaphylactic shock [178, 179]. Hypersensitivity can also be observed in the gastrointestinal
tract and to dermatological preparations containing PEG [180–184].
Another side effect to PEGylating compounds is the accelerated blood clearance (ABC)
phenomenon. In the first mention of the ABC phenomenon, PEGylated liposomes were
cleared at an accelerated rate during subsequent injection [185]. This observed effect further
potentiates the idea of the immune system playing an important role in reaction to PEG
molecules. The accelerated clearance may also indicate that size plays an important role, as
previous experiments have shown that size is an important factor when considering ABC
[186]. Perhaps, larger PEG molecules may elicit this effect to a greater degree. ABC is a
poorly understood mechanism and warrants further research in regard to PEG.
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PEG is an attractive therapeutic approach in cancer. Limiting systemic toxicity could provide
many benefits to cytotoxic therapeutics. Oncaspar® (pegaspargase), an L-asparaginase that
is covalently conjugated to PEG and mPEG, is FDA-approved for the treatment of acute
lymphoblastic leukemia [187], though no clinical trials are planned for BCBM. Another
PEGylated therapy being clinically investigated for BCBM is etirinotecan pegol
(NKTR-102). This novel therapy is a four-armed PEG polymer, with each arm ending with a
hydrolysable ester linker and an irinotecan molecule [188]. In its preclinical studies,
NKTR-102 was found to increase the duration of exposure and accumulation of SN-38 (the
active metabolite of irinotecan) into tumors when compared to conventional irinotecan.
[188]. NKTR-102-treatment improved survival in a triple-negative brain metastatic model
compared to conventional chemotherapy agents [189]. In the ATTAIN trial, BCBM patients
are being recruited to test the efficacy of NKTR-102, with a primary outcome of CNS
disease control rate (NCT02915744).
Another PEGylated cancer therapeutic which has completed an open-label, PhaseI/IIa
clinical trial is glutathione PEGylated liposomal doxorubicin (2B3-101). 2B3-101 showed
favorable improvements in overall survival in its preclinical studies over both PEGylated
liposomal doxorubicin and vehicle [152]. 2B3-101 is thought to have increased targeting
capabilities due to the presence of the glutathione acting as a targeting ligand [152]. The
recently completed trial, for which no results have been reported as of yet, assessed the
safety and tolerability of 2B3-101 in patients with brain metastases of solid tumors and
malignant glioma over 16 months as well as its combination with trastuzumab in patients
with HER2+ BCBM.

Author Manuscript

5.4 Physical devices
Several other therapeutic approaches hypothesized for treatment of primary brain tumors can
be extrapolated to treat metastatic tumors as well. These include use of convection-enhanced
therapy, Giladel® (carmustine) wafers, osmotic BBB disruption, and ultrasound mediated
BBB opening [190]. Ultrasound mediated disruption of BBB has been found to be effective
in enhancing large molecule delivery, such as trastuzumab therapy [191]. This technique has
been combined with using nanocarriers for drug delivery in brain metastases of breast
cancer. Ultrasound induced hyperthermia has been employed to deliver doxorubicin
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encapsulated in a liposomal carrier for brain metastasis of breast cancer [192]. Significantly
higher doxorubicin was measured in tumors with the combination as compared to treatment
with doxorubicin liposomes alone.

6. CONCLUSION
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The discovery of new biological targets has led to a resurgence and expansive interest in
chemotherapy and dosage forms. New agents inhibiting PARP, CDK 4/6, PI3K, ILGF-1,
estrogen pathways, HDAC, and HER2+ receptors and downstream effects, are being
combined with traditional options such as radiation and surgery to develop new strategies to
treat BCBM. Liposomes, conjugation to polymers, and nanoparticle sizing offer a route to
repurpose conventional chemotherapy via the enhanced permeation and retention effect,
which leads to reduced side effects, longer therapeutic windows, and less-frequent dosing
intervals. With the combination of improved pharmacokinetic profiles and targeted
chemotherapy, clinical trials are including patients with BCBM more frequently, and may
provide substantial therapeutic advances to significantly extend overall survival for this
diagnosis.

Acknowledgments
This research was supported by a grant from the National Cancer Institute (R01CA16606701A1). Additional
support for this research was provided through the National Institute of General Medical Sciences of the National
Institutes of Health (U54GM104942, P30 GM103488), and the American Foundation for Pharmaceutical
Education.

Abbreviations
Author Manuscript
Author Manuscript

ABC

accelerated blood clearance

BBB

blood-brain barrier

BCBM

breast cancer brain metastases

BTB

blood-tumor barrier

CNS

central nervous system

CDK

cyclin-dependent kinase

EPR

enhanced permeation and retention

ER

estrogen receptor

HDAC

histone deacetylase

HER2

human epidermal growth factor receptor 2

Hormone receptor

HR

mTOR

mammalian target of rapamycin

OS

overall survival
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P-gp

permeability glycoprotein

PARP

poly-ADP ribose polymerase

PEG

polyethylene glycol

PFS

progression-free survival

PI3K

phosphatidylinositide 3-kinase

PEG

polyethylene glycol

PR

progesterone receptor

SRS

stereotactic radiosurgery

T-DM1

trastuzumab emtansine

TNBC

triple negative breast cancer

VEGF

vascular endothelial growth factor

WBRT

whole-brain radiation therapy
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Table 1

Results of hormone positive BCBM clinical trials

Author Manuscript

Compared to standard chemotherapy, targeted agents have a better response rate and newer agents have fewer
side effects.
Combination

Outcomes

Anastrozole

Gefitinib

In a Phase II study, 108 patients received anastrozole with gefitinib or
placebo. The PFS at 1 year was 35% with gefitinib and 32% with placebo
while the median duration of response was 13.8 months with gefitinib and
18.6 months with placebo. The most common AE was fatigue (35%), rash
(32%), diarrhea (31%), dry skin (27%), and myalgia (27%) [193].

5-Azacitidine

Entinostat

In a Phase II study, 27 patients with HR+ and 13 with TN MBCB received
the combination. There was one PR in the HR+ group (ORR =4%), none in
the TN group, and one PR in an optional continuation group (n=12) [194].

Buparlisib

Fulvestrant

In a Phase I trial, 31 patients received this combination to determine the
MTD of buparlisib and assess preliminary efficacy. Of the 29 evaluable
patients, the clinical benefit rate was 58.6%. Commone AE were fatigue
(38.7%), elevated hepatic enzymes (35.5%), rash (29%), & diarrhea (19.4%)
[195].

Fulvestrant

In a Phase III trial, 576 patients received this combination with median PFS
of 6.9 months vs. 5 months in placebo group. The most common grade 3–4
AE were increased hepatic enzymes (~25%), hyperglycemia (15%), and rash
(8%) [196].

Paclitaxel

In a Phase III & III trial, 207 patients received this combination and 209
received a placebo with paclitaxel to measure PFS in Phase 2 before
progressing to Phase 3. The PFS with buparlisib was 8 months vs. 9.2
months with placebo. The trial did not enter Phase 3 due to futility [74].

Author Manuscript

Compound

Summary

This combination was
well-tolerated but the
primary endpoint (ORR
≥20%) was not achieved.

The results show that
PI3K inhibition combined
with endocrine therapy is
effective but no further
studies are being pursued
with this combination due
to the toxicity. Patients’
disease had to progress on
or after an AI and up to
one prior line of
chemotherapy.

Author Manuscript

Cabozantinib

In a Phase III discontinuation study, 45 patients received cabozantinib as a
12-week lead-in stage followed by a randomization stage to continue
cabozantinib or receive placebo. During the lead-in stage, ORR was 13.6%
and disease control rate at week 12 was 46.7%. The overall median PFS was
4.3 months and median OS was 11.4 months [197].

Active brain metastasis
was excluded but
cabozantinib
demonstrated clinical
activity in objective
response and disease
control.

Capecitabine

In a Phase III trial, 546 patients with MBCB received capecitabine. Overall
survival was 14.5 months and PFS was 4.2 months and 25 patients developed
new BCBM [66].

Capecitabine appears to
cross the BBB and have
activity in BCBM.

In a Phase II trial, 12 patients with BCBM first received capecitabine with
radiation therapy followed by capecitabine with sunitinib. The trial was
closed due to slow accrual but median PFS was 4.7 months and OS was 10
months [67].

There was no extension of
PFS and this combination
was considered
significantly toxic.

In a prospective study, 8 BCBM patients received capecitabine 2–3 hours
before surgical resection of BCBM tumor to assess drug levels in BCBM
tissue. There were measurable amounts of capecitabine and its metabolites in
BCBM tissue but BCBM to serum ratio was higher for 5-fluorouracil than
capecitabine [68].

Capecitabine was able to
penetrate the BBB, though
to a variable degree.

Sunitinib

Author Manuscript

WBRT

Z-Endoxifen

In this retrospective study, 5 BCBM patients received capecitabine with
WBRT. One patient had a complete response, two had partial responses and
one had stable disease [64].
In a Phase I trial, 38 HR+ endocrine-refractory MBCB patients received ZEndoxifen. Overall clinical benefit rate was 26.3% [198].
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Combination

Eribulin

Author Manuscript

Estradiol

Exemestane

Lapatinib

Outcomes

Summary

In a Phase III trial, 544 patients with MBCB received eribulin. Overall
survival was 15.9 months and PFS was 4.1 months and 13 patients developed
new BCBM [66].

Eribulin does not cross a
healthy BBB but may be
able to do so in
combination with
radiation therapy.

Sixty-six patients with pre-treated MBCB received eribulin monotherapy.
Median PFS was 5 months and OS was 8 months, 15 patients had PR, and 36
had stable disease [199].

Eribulin monotherapy was
deemed safe and effective
as a result of this study.

In a pilot study, 13 patients received estradiol and 6 (46%) had no
progression at 3 months and were then switched to exemestane. Of the 6 on
exemestane, 5 had disease progression and 1 had stable disease. Median PFS
was 4.8 months [200].
In a prospective study, 4 BCBM patients received 2–5 doses of lapatinib
daily with the last being 2–3 hours before surgical resection of BCBM tumor
to assess drug levels in BCBM tissue. The median BCBCM concentrations
ranged from 1.0–6.5 μM [68].

Author Manuscript
Author Manuscript

Paclitaxel

Pictilisib

In the Phase II PEGGY study, paclitaxel was combined with pictilisib or a
placebo for 183 eligible patients. The PFS for the pictilisib group was 8.2
months versus the placebo group which was 7.8 months [201].

Pilaralisib

Letrozole

In a Phase I & II dose escalation study, 21 patients were enrolled in Phase 1
to determine the MTD and 51 patients were enrolled in Phase II which
determined efficacy using the MTD. One patient had a PR and the rate of
PFS at 6 months was 17%. The most common grade ≥3 AE were increased
hepatic enzymes (5%) and rash (5%) [202].

Ramucirumab

Eribulin

In a Phase II trial, 141 MBCB patients received a combination of
ramucirumab and eribulin or eribulin alone. Median PFS for the combination
was 4.4 months versus 4.1 months for eribulin alone while OS was 13.5
months versus 11.5 months and ORR was 21% versus 28% [203].

Temozolomide

Capecitabine

In a Phase I trial, 24 patients received temozolomide combined with
capecitabine. Of the 24 patients, 1 had a complete response and 3 had partial
responses (ORR 18%) [63].

Vinorelbine

Thirty-six BCBM patients received temozolomide in combination with
vinorelbine and WBRT. There were 3 complete responses and 16 PR with an
ORR of 52%. The median PFS and OS were 8 and 11 months, respectively
[65].

Letrozole

In a Phase I & II dose escalation study, 21 patients were enrolled in Phase I
to determine the MTD and 51 patients were enrolled in Phase II which
determined efficacy using the MTD. No patients responded and the rate of
PFS at 6 months was 8%. The most common grade ≥3 AE were increased
hepatic enzymes (11%) and rash (9%) [202].

Voxtalisib

Lapatinib was able to
penetrate the BBB, though
to a variable degree.

The safety was acceptable
but the efficacy was
limited.

The safety was acceptable
but the efficacy was
limited.

AE: adverse events; MBCB: metastatic breast cancer of the brain, MTD: maximum therapeutic dose; ORR: overall response rate; OS: overall
survival; PFS: progression-free survival.
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Table 2

Author Manuscript

In-progress and upcoming clinical trials involving hormone-positive BCBM.

Author Manuscript
Author Manuscript
Author Manuscript

Compound

Trial

Phase and Status

Parameters

Comment

Abemaciclib

NCT02308020

Phase II, currently
recruiting

Must have brain
metastasis from
non-small cell lung
cancer, melanoma,
or HR+ breast
cancer that can be
HER2+/−.

Leptomeningeal
metastases were
excluded.

Abemaciclib + Trastuzumb +/−
Fulvestrant

NCT02675231 (monarcHER)

Phase II, currently
recruiting

Participants with
MBCB that is HR+/
HER2+ who
previously received
at least 2 HER2targeted therapies.
CNS metastases
were excluded if
untreated,
symptomatic, or
required steroids to
manage symptoms.

Abemaciclib

NCT02792725

Phase unknown,
offering expanded
access

Participants with
HR+/HER2−
MBCB. CNS
metastases requiring
immediate local
therapy are
excluded.

Alisertib (MLN8237) +
Fulvestrant

NCT02219789

Phase I, ongoing but
not recruiting

Participants with
HR+ MBCB. CNS
metastases treated
by surgery and/or
radiotherapy and
neurologically stable
and off steroids >12
weeks are eligible.

Alpelisib (BYL719) +
Fulvestrant

NCT02437318 (SOLAR-1)

Phase 3, currently
recruiting

Participants with
HR+/HER2−
MBCB. CNS
metastases were
excluded unless they
completed treatment
>4 weeks prior to
study with stable
CNS tumor at time
of study screening
and not taking
steroids or enzyme
inducing antiepileptic
medications.

Alpelisib + Tamoxifen +
Goserelin

NCT02058381 (B-YOND)

Phase I, ongoing but
not recruiting

Participants with
HR+/HER2−
MBCB.
Symptomatic CNS
metastases are
excluded.

Alpelisib + Letrozole

NCT01791478

Phase I, ongoing but
not recruiting

Participants with
HR+/HER2−
MBCB.
Symptomatic brain
metastases are
excluded, must be
clinically stable >4
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Anastrozole + Palbociclib

NCT02942355

Phase II, currently
recruiting

Participants with
HR+/HER2−
MBCB. Brain
metastases are
included if no
evidence of
progression >4
weeks after CNSdirected treatment.

Apitolisib (GDC-0980) +
Paclitaxel +/− Bevacizumab

NCT01254526

Phase I, completed

Participants with
MBCB but
untreated or active
CNS metastases are
excluded.

BMS-754807 +/− Letrozole

NCT01225172

Phase II, completed

Participants with
HR+/HER2−
MBCB, where those
with symptomatic
BM were excluded.

Buparlisib (BKM120) +
Tamoxifen + Goserelin

NCT02058381 (B-YOND)

Phase I, ongoing but
not recruiting

Participants with
HR+/HER2−
MBCB.
Symptomatic CNS
metastases are
excluded.

Buparlisib + Fulvestrant

NCT01610284 (BELLE-2)

Phase 3, ongoing but
not recruiting

Participants with
HR+/HER2−
MBCB, where those
with symptomatic
BM are excluded.

Participants’
MBCB had to
progress on or
after an AI.

Buparlisib + Fulvestrant

NCT01633060 (BELLE-3)

Phase 3, ongoing but
not recruiting

Participants with
HR+/HER2−
MBCB, where those
with symptomatic
BM were excluded.

Participants’
MBCB had to
progress on or
after mTOR
inhibitor.

Buparlisib + Paclitaxel

NCT01572727 (BELLE-4)

Phase II/3, completed

Participants with
known HR status
and HER2−, where
those with
symptomatic CNS
metastases were
excluded.

Buparlisib + Tamoxifen

NCT02404844 (PIKTAM)

Phase II, ongoing but
not recruiting

Participants with
HR+/HER2−
MBCB, where those
with symptomatic
CNS metastases
were excluded.

Participants had
prior treatment
with 1–2
antihormonal
therapies.

Buparlisib or Dactolisib +
Letrozole

NCT01248494

Phase I, completed

Participants with
HR+/HER2+/−
MBCB, where those
with symptomatic
BM were excluded.
History of BM must
be clinically stable
>4 weeks postradiation treatment
and >4 weeks after
steroid tapering.

Those with
HER2+ must have
previous
treatment with
trastuzumab.

Buparlisib + Capecitabine

NCT02000882

Phase II, ongoing but
not recruiting

Participants with
HR+/HER2−,
HER2+, or triplenegative MBCB

At least 1 CNS
lesion ≥5mm in at
least 1 dimension
with prior WBRT.
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Cabozantinib +/− Trastuzumab

NCT02260531

Phase II, currently
recruiting

Participants must
have CNS lesions
but leptomeningeal
cannot be the only
CNS metastasis.

This study has
three arms,
HER2+, HR+,
and triplenegative.

Cabozantinib + Fulvestrant

NCT01441947

Phase II, ongoing but
not recruiting

Participants with
HR+/HER2−
MBCB with bone
involvement.
Untreated,
symptomatic brain
metastases requiring
current treatment
with steroids and
anti-convulsants are
excluded.

Participants must
have received ≥1
prior line of
hormonal therapy
or chemotherapy.

Capecitabine + Pegylated
Interferon Alfa-2a

NCT00227656

Phase II, terminated
(study slow to accrue)

Participants must
have CNS
metastases that has
not progressed on
prior treatment with
capecitabine,
fluorouracil,
interferon alfa, or
interferon beta.

HR status not
specified.
Participants must
have stable
systemic cancer.

Capecitabine + WBRT

NCT00977379 (XERAD)

PhaseII, terminated
(insufficient number of
participants enrolled)

Participants with
known HR/HER2
status and newly
diagnosed CNS
metastases with at
least one lesion ≥1
cm or two lesions
0.5–1 cm.

Leptomeningeal
disease is
excluded, as is
prior treatment for
brain metastases.

Capecitabine + Sunitinib +
WBRT

NCT00570908

Phase II, terminated
(poor accrual)

Participants must
have measurable
CNS metastases
without prior
WBRT.

HR/HER2 status
not specified.

Capecitabine + AI (Anastrozole
or Letrozole or Exemestane)

NCT02767661 (MECCA)

Phase 3, not yet open
for recruitment

Participants must
have HR+/HER2−
MBCB. Known
uncontrolled or
symptomatic CNS
metastases are
excluded.

Dactolisib (BEZ235)

NCT01288092

Phase II, withdrawn
prior to enrollment

Participants must
have HR+/HER2−
MBCB, without
symptomatic CNS
metastases.

Elacestrant (RAD-1901)

NCT02650817

Phase I, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB but
symptomatic CNS
metastases are
excluded.

Elacestrant

NCT02338349

Phase I, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB but
untreated or
symptomatic CNS
metastases are
excluded.
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Z-Endoxifen HCl

NCT01273168

Phase I, currently
recruiting

Participants must
have HR+ solid
tumor of any type
and those with brain
metastases are
excluded unless
remained stable ≥3
months after
treatment, without
steroids or antiseizure medications.

Participants with
MBCB must have
had at least 1
prior
chemotherapy
regimen.

Entinostat (SNDX-275) +
Exemestane

NCT02833155

Phase I, currently
recruiting

HR+ MBCB in
Chinese women and
CNS metastases are
included if no
steroids and stable
disease ≥1 month.

Disease
progression posttreatment with a
non-steroidal AI.

Entinostat + AI

NCT00828854

Phase II, completed

Participants with
HR+ MBCB where
known active brain
metastasis is
excluded.

Progressive
disease following
>3 months
treatment with 3rd
generation AI.

Entinostat + Erlotinib +
Exemestane

NCT01594398

Phase I, completed

Participants with
HR+ MBCB or
NSCLC and brain
metastasis is
included if certain
criteria are met.

Entinostat + Nivolumab +
Ipilimumab

NCT02453620

Phase I, currently
recruiting

Participants must
have HER2− MBCB
that can be HR+ and
brain metastasis is
included if stable for
>4 weeks and off
steroids >2 weeks.

At least 1 prior
chemotherapy
regimen and 2
lines of hormone
therapy.

Eribulin Mesylate +/−
Pembrolizumab

NCT03051659

Phase II, currently
recruiting

Participants with
HR+ MBCB and
brain metastases are
eligible if they
completed treatment
≥4 weeks prior to
registration and
discontinue steroids
≥2 weeks before
beginning study and
remained symptomfree.

Participants must
have received at
least 2 lines of
hormonal therapy
and can receive
up to 2 lines of
chemotherapy.

Erlotinib (BMS-690514) +
Letrozole

NCT01068704

Phase II, completed

Participants had HR
+ MBCB but
symptomatic BM
were excluded.

HER2+/− were
accepted and
participants had
disease
progression
despite treatment
with tamoxifen,
anastrozole, or
exemestane.

Esterified Estrogens

NCT00131924

Phase II, terminated
(poor accrual)

Participants must
have HR+ MBCB
where BM are
included provided
participants received
previous treatment
for BM, are stable,
and BM are not the
only site of
metastasis.

Participants’
disease must have
progressed
following
treatment with at
least 2 prior
endocrine
therapies.
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Estradiol + Exemestane

NCT01385280

Pilot study, completed

Participants must
have HR+ MBCB
and treated CNS
metastases are
included.

Participants must
have had prior AI
therapy.

Everolimus + Letrozole +
Trastuzumab

NCT02152943

Phase I, currently
recruiting

Participants must
have HR+/HER2+
MBCB where CNS
metastases are
included if
previously treated
and stable for 3
weeks and off
steroids and
anticonvulsants.

Leptomeningeal
disease is
excluded.

Everolimus + Anti-Estrogen

NCT02291913

Phase II, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB where BM
are eligible if treated
≥2 weeks before
study and not
currently receiving
enzyme inducing
anti-epileptic drugs
or steroids.

Everolimus

NCT02387099 (Desiree)

Phase II, currently
recruiting

Participants with
HR+/HER2−
MBCB who do not
have symptomatic
visceral metastases.
Brain metastases are
included if
previously treated
by surgery and/or
radiotherapy.

Everolimus + AI

NCT02511639 (MAIN-A)

Phase 3, currently
recruiting

Participants have
HR+/HER2−
MBCB where
symptomatic CNS
metastases are
excluded.

Participants must
have received 1
line of prior
chemotherapy.

Everolimus + Hormone
Therapy

NCT02269670

Phase II, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB where
uncontrolled CNS
metastases are
excluded.

Participants
demonstrate
disease
progression on
everolimus and
exemestane
combination.

Everolimus + Letrozole +
Leuprorelin

NCT02344550 (LEO)

Phase II, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
symptomatic BM
are excluded.

Must have
progressive
disease after
treatment with
tamoxifen +/−
GnRH agonist.

Exemestane + Sunitinib

NCT00905021 (EXTENT)

Phase I & II,
terminated (sponsor
withdrew support)

Participants with
HR+ MBCB and
CNS metastases is
allowed if stable for
>3 months.

HER2+ is allowed
but must have
failed treatment
with trastuzumab.

Fulvestrant + Everolimus +
Exemestane

NCT02404051 (FEVEX)

Phase 3, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
symptomatic CNS
metastases are
excluded.
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Fulvestrant +/− Ganetespib

NCT01560416

Phase II, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB, where
untreated or
progressive brain
metastases are
excluded.

Fulvestrant + MK-0646 +
Dasatinib

NCT00903006

Phase I & II,
terminated (low
accrual)

Participants have
HR+/HER2−
MBCB, where
active or untreated
BM were excluded.

Fulvestrant +/− Lapatinib

NCT00390455

Phase 3, ongoing but
not recruiting

Participants have
HR+/HER2+/−
MBCB and
asymptomatic CNS
metastases or BM
that is >3 months
past treatment are
eligible.

Participants must
have received
prior treatment
with 1–2
endocrine
therapies and
third-generation
AI.

G1T38 + Fulvestrant

NCT02983071

Phase I & II, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
active, uncontrolled,
symptomatic CNS
metastases are
excluded.

Participants’
disease must have
progressed on or
after treatment
with an AI or
tamoxifen.

GDC-0077 + Fulvestrant +
Letrozole + Palbociclib

NCT03006172

Phase I, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
active, untreated
CNS metastases are
excluded.

Participants have
PIK3CA
mutation.

GDC-0810 + Letrozole and/or
LHRH Agonist

NCT01823835

Phase I & II, ongoing
but not recruiting

Participants have
HR+/HER2−
MBCB, where
untreated,
symptomatic CNS
metastases are
excluded.

Participants’
disease must have
progressed after
≥6 months of
hormonal therapy.

IMP321 + Paclitaxel

NCT02614833 (AIPAC)

Phase II, currently
recruiting

Participants have
HR+ MBCB but
symptomatic CNS
metastases are
excluded.

Irinotecan + Temozolomide

NCT00617539

Phase II, completed

MBCB with BM
that has progressed
following treatment.

Hormone receptor
status not
specified.

Lapatinib

NCT00759642

Phase II, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB, where CNS
metastases are
eligible if >3
months from
treatment and
asymptomatic.

Must have disease
progression on or
after treatment
with AI and/or
fulvestrant.

Lenvatinib + Letrozole

NCT02562118

Phase I & II, currently
recruiting

Participants have
HR+ BC but
symptomatic BM
are excluded.

Letrozole + Celecoxib

NCT00101062

Phase II, terminated
(study drug
unavailable)

Participants had HR
+ MBCB, where
BM were included if
controlled by
radiotherapy or
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MK-2206 + Exemestane +
Goserelin

NCT01240928

Phase I, withdrawn
(funding not available)

Participants had HR
+ BC and CNS
metastases were
included if stable for
>1 month prior to
study.

MK-2206 + Exemestane +
Goserelin

NCT01240941

Phase II, withdrawn
(funding not available)

Participants had HR
+ BC and CNS
metastases were
included if stable for
>1 month prior to
study.

Paclitaxel + Pictilisib

NCT01740336 (PEGGY)

Phase II, completed

Participants had HR
+/HER2− MBCB
but untreated or
active CNS
metastases were
excluded.

Palbociclib + Anti-HER2
Therapy + Endocrine Therapy

NCT02947685 (PATINA)

Phase 3, currently
recruiting

Participants have
HR+/HER2+
MBCB and CNS
metastases are
eligible if no
progression after
CNS directed
therapy and >3
weeks between
radiotherapy and
study start.

Palbociclib + Tamoxifen

NCT02668666

Phase II, currently
recruiting

Participants have
HR+ MBCB and
BM are eligible after
tumors have been
treated with
resection and/or
radiotherapy and
neurologically stable
>1 month off
steroids.

Palbociclib + Letrozole or
Fulvestrant

NCT02692755 (PALINA)

Phase II & 3, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
uncontrolled or
symptomatic BM
are excluded.

Palbociclib + Everolimus +
Exemestane

NCT02871791

Phase I & II, currently
recruiting

Participants have
HR+/HER2−
MBCB and CNS
metastases are
included if treated
by surgery or
radiotherapy with
>3 months of stable
disease, not
requiring steroids or
enzyme inducing
anti-epileptic
medications.

Palbociclib + Fulvestrant

NCT01942135 (PALOMA-3)

Phase 3, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB, where
uncontrolled or
symptomatic CNS
metastases are
excluded.
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Palbociclib + Letrozole

NCT02600923

Phase 3, currently
recruiting

Participants have
HR+/HER2−
MBCB and treated,
clinically stable BM
are permitted.

Palbociclib + Fulvestrant

NCT02738866

Phase II, currently
recruiting

Participants have
HR+/HER2−
MBCB and CNS
metastases are
allowed if treated
and stable.

Disease
progression on
prior treatment
with palbociclib +
AI.

Palbociclib + Exemestane +
Goserelin

NCT02917005 (FATIMA)

Phase II, not yet open
for recruitment

Participants have
HR+/HER2−
MBCB, where
uncontrolled CNS
metastases are
excluded.

Women must be
premenopausal.

Palbociclib + AI or Fulvestrant

NCT02894398 (INGE-B)

Phase II, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
known nonirradiated CNS
metastases are
excluded.

Palbociclib + Bazedoxifene

NCT02448771

Phase I & II, currently
recruiting

Participants have
HR+/HER2−
MBCB and treated
BM not requiring
steroids are eligible.

Palbociclib + Fulvestrant or
Tamoxifen

NCT02384239

Phase II, currently
recruiting

Participants have
HR+/HER2−
MBCB and CNS
metastases are
eligible if
definitively treated
by radiotherapy or
surgery, are stable,
and off steroids and
anticonvulsants >4
weeks before
beginning study.

Palbociclib + Exemestane +
Leuprolide Acetate

NCT02592746

Phase II, currently
recruiting

Participants have
HR+/HER2−
MBCB and treated
and stable BM are
included.

Participant must
be
premenopausal.

Palbociclib + Taselisib or
Pictilisib

NCT02389842 (PIPA)

Phase I, status
unknown

Participants have
HR+ MBCB that
can be HER2+/−
and untreated or
active CNS
metastases are
excluded.

HR+ must have
progressed on ≥1
prior endocrine
therapy; PIK3CA
must have
progressed on ≥1
prior endocrine or
chemotherapy.

Pembrolizumab (MK-3475) +
Doxorubicin or Anti-Estrogen
Therapy

NCT02648477

Phase II, currently
recruiting

Participants have
HR+/HER2− or
triple-negative
MBCB and CNS
metastases may
participate if stable
and not using
steroids >7 days
before trial.

Pictilisib (GDC-0941) or
GDC-0980 + Fulvestrant

NCT01437566

Phase II, completed

Participants have
HR+/HER2−
MBCB where
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Ribociclib (LEE011) +
Letrozole

NCT03096847

Phase 3, currently
recruiting

Participants have
HR+/HER2−
MBCB and CNS
metastases are
eligible if prior
therapy is completed
≥28 days before
study, CNS tumors
are stable, and
patient is not using
steroids or enzyme
inducing antiepileptic
medications.

Ribociclib + Fulvestrant

NCT02422615 (MONALEESA-3)

Phase 3, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB and CNS
metastases are
eligible if prior
treatment completed
>4 weeks before
study, stable, and
not taking steroids
or enzyme inducing
anti-epileptic
medications.

Ribociclib + PDR001 +/−
Fulvestrant

NCT03294694

Phase I, not yet open
for recruitment

Participants have
HR+/HER2−
MBCB and CNS
metastases are
included if prior
treatment completed
>4 weeks before
study, stable, and
not using steroids or
enzyme inducing
anti-epileptic
medications.

Study includes
ovarian cancer.

Ribociclib + Fulvestrant

NCT02632045

Phase II, currently
recruiting

Participants have
HR+/HER2−
MBCB and CNS
metastases are
eligible if definitive
treatment and
steroids are
completed >4 weeks
before study.

Participants must
have disease
progression on
prior AI or CDK
4/6 inhibitor.

Ribociclib + Letrozole +
Alpelisib

NCT01872260

Phase I, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
active CNS
metastases are
excluded.

Ribociclib + Tamoxifen

NCT02586675 (TEEL Study)

Phase I, ongoing but
not recruiting

Participants have
HR+/HER2−
MBCB but CNS
metastases are
excluded unless
specific criteria are
met.

Seribantumab + Fulvestrant

NCT03241810 (SHERBOC)

Phase II, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
uncontrolled CNS
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Sonidegib (LDE225) +
Buparlisib (BKM120)

NCT01576666

Phase I, completed

Participants have
MBCB and CNS
metastases are
eligible if
controlled,
asymptomatic, and
stable.

Study includes
pancreatic
adenocarcinoma,
colorectal cancer,
and glioblastoma
multiforme.

Sorafenib (BAY 43-9006) +
Capecitabine

NCT01234337

Phase 3, ongoing but
not recruiting

Participants with
HER2− MBCB but
active brain
metastasis is
excluded.

Participants must
have received up
to 2 prior
chemotherapy
regimens one of
which must
include an
anthracycline.

Taselisib (GDC-0032) +/−
Fulvestrant or Letrozole

NCT01296555

Phase I & II, currently
recruiting

Participants have
HR+/HER2−
MBCB, where
active, untreated
CNS metastases are
excluded.

Study includes
Non-Hodgkin’s
Lymphoma.

Taselisib + Fulvestrant

NCT02340221 (SANDPIPER)

Phase 3, currently
recruiting

Participants must
have HR+/HER2−
MBCB, where
active, untreated
CNS metastases are
excluded.

Temozolomide + WBRT

NCT02133677

Phase II, status
unknown

Participants must
have BM from BC
or lung cancer.

Hormone status
not specified.

Temozolomide + Radiation

NCT00875355

Phase II, status
unknown

Participants must
have BM from BC.

Hormone status
not specified.

Tucatinib + Palbociclib +
Letrozole

NCT03054363

Phase I & II, not yet
open for recruitment

Participants have
HR+/HER2+
MBCB and CNS
metastases are
included if
asymptomatic or
previously treated
and off steroids for
>4 weeks before
study.

Voxtalisib (XL765;
SAR245409) or Pilaralisib
(XL147; SAR245408) +
Letrozole

NCT01082068

Phase I & II,
completed

Participants have
HR+/HER2−
MBCB, where
untreated,
symptomatic, or
progressive BM are
excluded.

Disease is
refractory to
nonsteroidal AI.

Xentuzumab (BI 836845) +
Abemaciclib +/− Hormonal
Therapy

NCT03099174

Phase I, currently
recruiting

Participants have
HR+/HER2−
MBCB and CNS
metastases are
eligible if treated
and stable, off
steroids and
anticonvulsants >4
weeks.

Study includes 1
cohort of nonsmall cell lung
cancer.

MBCB: metastatic breast cancer.
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Outcomes

Cisplatin

Bevacizumab

In a Phase II trial of 35 patients pre-treated with bevacizumab and
then given cisplatin and etoposide, 25 patients (77%) achieved a
response rate. [91]

Etoposide

In a Phase II trial of 4 BCBM patients, 1 achieved a PR. [204]
In 56 patients treated with the combination, 7 achieved CR, 14 PR,
12 did not change, 16 progressed, and 8 were not assessed, for an
overall 38% response rate. [90]

Doxorubicin

Cisplatin, doxorubicin, methotrexate and 5-fluorouracil caused
major toxicity with no improvement in 4 BCBM patients. [205]

Cyclophosphamide

6 patients achieved a PR in a Phase II trial of 15 patients with
BCBM. [92]

Gemcitabine

In a trial of 15 BCBM, 4 of 6 were triple negative and achieved a
response. [94]

Vinorelbine

In combination with a 30 Gy radiation schedule, a Phase II trial of
25 patients with cisplatin and vinorelbine resulted in 3 CR and 16
PR (76%). [93]

Cisplatin

See cisplatin.

Methotrexate, 5fluorouracil, vincristine,
doxorubicin

Cyclophosphamide, methotrexate, and 5-fluorouracil were given to
20 patients with 13 attaining a positive response. [206]
In 56 patients treated with cyclophosphamide, methotrexate, 5fluorouracil and doxorobucin, PFS lengthened but no significant
intracranial metastases-free interval. [207]
In 27 of 52 patients (52%) with BCBM, response was achieved
with cyclophosphamide, 5-fluorouracil and prednisone, 19 of 35
patients (54%) achieved response with cyclophosphamide, 5fluorouracil, prednisone, methotrexate and vincristine, and 1 of 6
(17%) achieved response with cyclophosphamide and doxorubicin.
[208]

Cisplatin

See cisplatin.

Cyclophosphamide

See cyclophosphamide.

Topotecan, ifosfamide

5 BCBM patients treated with the triple combination, with
progressive disease occurring 2 of 5. [209]

Teniposide, lomustine

8 patients were treated with this triple therapy, 5 showed
improvement and symptom regression. [210]

Cyclophosphamide

Doxorubicin

Author Manuscript

Eribulin

5-fluorouracil

Author Manuscript

Gemcitabine

Summary

Though it has poor
CSF penetration,
cisplatin can
penetrate the bloodtumor barrier.

In one patient, eribulin was initiated as fifth-line therapy. Response
was seen after one month, but ultimately the patient succumbed.
[211]
In three heavily treated patients, eribulin was found to be
beneficial. [66]
With concurrent whole-brain radiation therapy, eribulin regressed
two brain metastases. [212]
Cisplatin

See cisplatin.

Cyclophosphamide

See cyclophosphamide.

Cisplatin

See cisplatin.

Vinorelbine

In a Phase II trial of 3 evaluated BCBM patients, 1 had PR while 2
remained stable. 2 patients had leptomeningeal involvement. [214]
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Though it can cross
the blood-brain and
blood-tumor barrier,
5-fluorouracil is not
used as monotherapy,
always as a
combination agent.
[213]
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Author Manuscript

Compound

Combination

Outcomes

Summary

Irinotecan

Temozolomide

The combination was studied in NCT00617539, but results are not
posted or published.

Irinotecan is not
typically used in
brain metastases
treatment, but may
find utility in
combination with
newer treatment
modalities.

Iniparib

Of 34 evaluatable patients in a Phase II trial, 4 (12%) achieved a
CR, 13 (41%) achieved stable disease state, for a total of 27%
achieving a clinical benefit. [215]

Paclitaxel

Of 152 metastatic breast cancer patients, 78 (51%) responded to
paclitaxel while 6 (4%) developed progression. [216]

Author Manuscript

Bevacizumab

Of 4 patients treated with the combination, 1 achieved CR and 3
achieved PR. No patients showed progression. [217]
2 patients achieved PR, 2 achieved stable disease, and 1 progressed
when given combination therapy. [218]

Vinorelbine

6 patients achieved a minor response, which unfortunately
progressed. [219]
In a Phase II trial of 11 BCBM patients, only 1 achieved a minor
response, while others were grouped into stable or progressing
disease. [220]

Temozolomide

Veliparib

In a 25 patient Phase I trial, in combination with whole brain
radiation therapy, median survival was 7.7 months compared to a
predicted 4.9 months. [221]

Author Manuscript
Author Manuscript
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The brain is
considered a
“sanctuary site” from
paclitaxel, due to its
low brain and CSF
concentrations.
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Table 4

Completed clinical trials of HER2+ BCBM

Author Manuscript

Patients receiving HER2-targeted therapy have improvements in overall and progression-free survival. Despite
poor intracranial penetration, trastuzumab alone or with emtansine have good outcomes compared to
chemotherapy or placebo.
Compound

Combination

Trastuzumab

Outcomes
The registHER study found that HER2+ BCBM patients who received
trastuzumab following CNS disease diagnosis (n=258) had a median
survival of 17.5 months as opposed to patients who did not receive
trastuzumab (n=119) having a median survival of 3.7 months.

Lapatinib

Capcitabine

Author Manuscript

Trastuzumab emtansine (T-DM1)

HER2+ BCBM patients treated with LC combination (n=30) had a median
OS of 27.9 months compared to patients treated with trastuzumab beyond
brain progression only (n=23) having a median OS of 16.7 months.
In the single-group phase 2 LANDSCAPE study, 29 of 44 HER2+ BCBM
patients (65.9%) had an objective CNS response to LC combination
treatment.
HER2+ BCBM patients treated with LC combination (n=46) had a median
survival of 19.1 months compared to patients treated with trastuzumabbased therapy (n=65) having a median OS of 12 months.
The phase 3 EMILIA study found that HER2+ BCBM patients treated with
T-DM1 (n=45) had a median OS of 26.8 months compared to patients who
received LC combination treatment (n=50) having a median OS of 12.9
months.
T-DM1 was shown to significantly decrease index lesion size (M1: from
1.6 cm to 0.8 cm) in one HER2+ BCBM patient.
Of 10 HER2+ BCBM patients treated with T-DM1, 3 had partial remission,
2 had stable disease lasting for ≥ 6 months, 2 had stable disease for < 6
months, and 3 progressed.
All 4 HER2+ BCBM patients treated with T-DM1 had 30% or greater
reduction in tumor size, and 1 was maintained on therapy for 16 months.
T-DM1 was administered to 39 HER2+ BCBM patients; median PFS was
6.1 months and one-year OS rate was 58%.
The phase 3 TH3RESA trial found that HER2+ BCBM patients who
received T-DM1 (n=404) had a median OS of 22.7 months compared to
patients who received treatment of physician’s choice (TPC) (n=198)
having a median OS of 15.8 months.

Author Manuscript

OS: overall survival; PFS: progression-free survival.

Author Manuscript
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Table 5

Upcoming clinical trials for HER2+ BCBM

Author Manuscript

The success of lapatinib, capecitabine, trastuzumab and its conjugation to emtansine, have led these agents to
be backbone therapy in the majority of newly initiated or in-progress trials for patients with HER2+ BCBM.

Author Manuscript
Author Manuscript
Author Manuscript

Compound

Trial

Phase and Status

Parameters

Comment

T-DM1 + Sequential Brain RT

NCT02135159

1, complete.

No previous WBRT or
leptomeningeal disease.

No study results posted.

Lapatinib + WBRT + Herceptin

NCT00470847

1, complete.

No previous WBRT or other
concurrent hormonal or
chemotherapy.

Median OS of 19
months.

Lapatinib + Temozolomide

NCT00614978

1, complete.

Steroids and previous trastuzumab
allowed.

No study results posted.

ARRY-380 + Trastuzumab

NCT01921335

1, active, not
recruiting.

No radiation or chemotherapy
>14 days before enrollment, no
seizure history.

No study results posted.

Pertuzumab + Trastuzumab

NCT02598427

1, Terminated in Feb
2018.

No seizures or WBRT, no seizure
or neuropsychiatric history.

Intrathecal
administration of
antibodies.

T-DM1 + Metronomic
Temozolomide

NCT03190967

1 and 2, recruiting

No WBRT or symptomatic brain
metastases or cardiac issues.

For secondary
prevention of HER2+
BCBM following SRS

Afatinib + Vinorelbine

NCT01441596

2, complete

Previous HER2+ tyrosine kinase
use other than lapatinib not
allowed, chemotherapy
discontinued at least 14 days prior
to enrollment.

No OS benefit vs. TPC

Everolimus + Trastuzumab +
Vinorelbine

NCT01305941

2, active, not
recruiting

No prior mTOR inhibitors or
cardiac history, stable on
dexamethasone, >4 weeks after
cranial surgery.

65% of 26 patients had
stable disease with
about 4 months to
intracranial
progression.

Lapatinib

NCT00263588

2, active, not
recruiting

No neuropsychiatric or cerebral
vascular diseases.

No study results posted.

Surgical Resection + Neratinib

NCT01494662

2, active, not
recruiting

2 week washout of prior therapy
and radiation, no concurrent
hormonal therapy, no antiepileptic
drugs.

49% had volumetric
reduction, 24% had
overall response rates
with a 6 month
progression-free
survival and a 13.5
month median overall
survival.

Palbocicib + Trastuzumab

NCT02774681

2, recruiting

Stable corticosteroid use, with no
HER2+ therapy other than
trastuzumab allowed.

No study results posted.

Lapatinib Ditosylate + SR or
WBRT

NCT01622868

2, recruiting

No prior radiation and concurrent
lapatinib therapy, cardiovascular
issues.

No study results posted.

Tucatinib + Capecitabine +
Trastuzumab

NCT02614794

2, recruiting

No lapatinib within 12 months, no
neratinib or HER2+ agent or
capecitabine prior.

No study results posted.

Cabozantinib + Trastuzumab

NCT02260531

2, recruiting

Previous c-Met use, seizure
history, prior lapatinib use within
1 week of starting.

No study results posted.

T-DM1 (Kadcyla)

NCT03203616

2, not yet recruiting.

Must have >1 metastases, cannot
have hormonal therapy within 14
days or trastuzumab within 21
days of enrollment.
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SR: stereotactic radiation; TPC: treatment of physician choice; WBRT: whole-brain radiation therapy.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
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